Share

July 14, 2020; 95 (2) Article

Longitudinal structural and metabolic changes in frontotemporal dementia

Alexandre Bejanin, Gautam Tammewar, Gabe Marx, Yann Cobigo, Leonardo Iaccarino, John Kornak, Adam M. Staffaroni, Bradford C. Dickerson, Bradley F. Boeve, David S. Knopman, Marilu Gorno-Tempini, Bruce L. Miller, William J. Jagust, Adam L. Boxer, Howard J. Rosen, Gil D. Rabinovici
First published June 26, 2020, DOI: https://doi.org/10.1212/WNL.0000000000009760
Full PDF
Short Form
Citation
Permissions

Make Comment

See Comments

Downloads
173

Share

Article Information

vol. 95 no. 2 e140-e154
DOI: 
https://doi.org/10.1212/WNL.0000000000009760
PubMed: 
32591470
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received April 2, 2019
  • Accepted in final form December 13, 2019
  • First Published June 26, 2020.

Article Versions

Copyright & Usage: 
© 2020 American Academy of Neurology

Author Disclosures

    1. Alexandre Bejanin, PhD,
    2. Gautam Tammewar, BA,
    3. Gabe Marx, BA,
    4. Yann Cobigo, BA,
    5. Leonardo Iaccarino, PhD,
    6. John Kornak, PhD,
    7. Adam M. Staffaroni, PhD,
    8. Bradford C. Dickerson, MD,
    9. Bradley F. Boeve, MD,
    10. David S. Knopman, MD,
    11. Marilu Gorno-Tempini, MD, PhD,
    12. Bruce L. Miller, MD,
    13. William J. Jagust, MD,
    14. Adam L. Boxer, MD, PhD,
    15. Howard J. Rosen, MD and
    16. Gil D. Rabinovici, MD
  1. Alexandre Bejanin, PhD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Gautam Tammewar, BA,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Gabe Marx, BA,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Yann Cobigo, BA,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Leonardo Iaccarino, PhD,
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. John Kornak, PhD,
    7. Scientific Advisory Boards:

    1. (1) UC Davis DSMB member for study of “Phase II RCT of High- dose Vitamin D Supplements in Older Adults without Dementia”, (Grant Number: AG051618; PI: John M. Olichney)

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. University of California, San Francisco (UCSF), Professor of Biostatistics

    Consultancies:

    1. (1) Biostatistical consulting at UCSF (2) Consulting as an expert witness on legal cases -- Latham & Watkins, Winston & Strawn

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. U01 CA15123 (Hylton) 9/26/11 – 08/31/16 1.2 calendar NIH/NCI $493,969 Quantitative Imaging for Assessing Breast Cancer Response to Treatment The goal of this project is the improved integration of MRI-based quantitative imaging (Q1) for evaluating response to treatment in clinical trials of women receiving pre-operative (neoadjuvant) treatment for breast cancer. Komen SAC 110017 (Hylton)                                                12/10/10-12/09/15                1.2 calendar Susan G. Komen for the Cure                                                $180,354 MR Imaging Phenotypes of Breast Cancer                                                                              The goal of this project is to develop and evaluate high spatial resolution non-contrast approaches for evaluating breast tissue. UL1 RR024131(Grandis) 7/1/11 – 6/30/16 1.5 calendar NIH-NCRR $17,231,623 Clinical and Translational Science Institute The overarching goal of the Clinical and Translational Science Institute (CTSI) is to create an integrated academic home that transforms training in and conduct of clinical and translational research both at UCSF and the greater Bay Area community. Components of the CTSI include formal didactic programs, career development pathways, a variety of consultative and technical Cores, and community outreach. Dr. Bacchetti leads the biostatistical consulting service. U01AG045390 (PI Boeve Subcon PI Rosen)                   9/30/14-5/31/19                        1.2 calendar Mayo Foundation/Mayo Clinic                                         $579,721 Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects (LEFFTDS) The role of UCSF in the grant will be two-fold. First, UCSF will be one of three sites enrolling f-FTLD family members and performing clinical and longitudinal follow-up. UCSF will take primary responsibility for processing T1 weighted MRIs for cortical thickness, and for doing the primary PET and icfMRI processing. Lastly, UCSF will manage the secure online database that will permit direct entry of the study data from each clinical site, and assist all investigators with database queries as needed. U54NS092089 (Boxer) 9/30/14 – 7/31/19 .6 calendar NIH/NINDS $1,250,000 Title: The Frontotemporal Lobar Degeneration Clinical Research Consortium Grants Officer: Grants Management Specialist: Allison Bailey Email: baileyall@mail.nih.gov Phone: 301-496-7392 Fax: 301-451-5635 Goal: The overarching goal of this proposal is to build a FTLD clinical research consortium (FTLD CRC) to support the development of FTLD therapies. C1CMS331346-01-010 (Miller) 9/1/14-8/31/17 1.2 calendar CMS The Centers for Medicare and Medicaid Services $2,721,047 Title: The UCSF and UNMC Dementia Care Ecosystem: Using Innovative Technologies to Personalize and Deliver Coordinated Dementia Care Goal: Most dementia care today is crisis-oriented. To break away from the cycle of stressful and costly issues that arise from a reactive approach, the Care Ecosystem will emphasize coordinated, continuous and personalized care. This proactive care model aims to improve health and satisfaction for participants and their caregivers. The study will also try to reduce avoidable emergency room visits, hospitalizations, or institutionalization, such as entering a nursing home R01HL128679 (Hu)                                             7/20/2015-04/30/19                                .96 calendar NIH/NHLBI                                                           $335,195        Develop&validate SuperAlarm to Detect Patient Deterioration with Few False Alarms             Critical care patient monitoring remains unsatisfactory as evidenced by the alarm fatigue problem it has created. We propose to develop a data fusion framework to integrate monitor alarms, laboratory test results, and other non-monitored physiological variables to realize a more precise way of monitoring patients to provide early detection of patient crisis events with few false alarms. Our project will lead to a potentially transformative paradigm change of critical care patient monitoring towards a more integrated and precise system for recognizing crisis events and enabling early interventions and produce a database to the community to propel further development of predictive models. R01EB022055-01A1 Kornak (PI) 04/15/17 - 01/31/21 NIH/NIBIB Bayesian image analysis in Fourier space The objective of this grant is to develop a family of new medical imaging processing methods that will advance the state-of-the art in radiological research and diagnostic evaluation. The approach is to reformulate Bayesian Image analysis into Fourier Space (BIFS). Fourier space independence enables powerful and easy to specify BIFS models with fast algorithms to compute posterior image estimates. Role: Principal Investigator 1U19 AG063911-01 Boeve (PI) 09/15/19 – 06/30/24 NIH ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) The goal of this project is to examine familial and non-familial frontotemporal lobe dementia. It integrates ARTFL and LEFFTDS into a single new consortium. Role: Co-Investigator U54NS092089 Boxer (PI) 09/30/14–07/31/19 NIH/NINDS Now in 2nd no-cost extension Title: The Frontotemporal Lobar Degeneration Clinical Research Consortium Goal: The overarching goal of this proposal is to build a FTLD clinical research consortium (FTLD CRC) to support the development of FTLD therapies. R01CA132870 Hylton (PI) 04/28/08-06/30/20 NIH Real-time In Vivo MRI Biomarkers for Breast Cancer Pre- Operative Treatment Trials The goal of this project is to develop and optimize MR imaging biomarkers for the assessment of breast cancer response to pre- operative treatment. Role: Co-Investigator R01CA227763 Hylton (PI) 02/01/19-01/31/24 NIH/NCI Dedicated breast PET and MRI for characterization of breast cancer and its response to therapy The objective of this academic-industrial partnership (AIP) project is to demonstrate the utility of dedicated breast positron emission tomography (dbPET) for characterizing primary breast cancers and their response to neoadjuvant chemotherapy (NAC). Role: Co-Investigator

    Research Support, Academic Entities:

    1. Bluefield Project (Seeley)                                         6/01/15 – 05/31/17  0.6 calendar Bluefield Project to Cure FTD                                       $191,197 Yr01 DC                 Disease detection and monitoring: neuroimaging biomarkers for GRN mutation-related frontotemporal dementia In this application, we propose to take on these challenges for a specific form of frontotemporal dementia (FTD) caused by mutations in GRN, which result in progranulin haploinsufficiency and a variable age at dementia onset, most commonly in mid-life. Evidence from our group and others suggests that GRN-related symptomatic FTD (henceforth “GRNFTD”) can be viewed as a network-based disorder in which TDP-43 inclusions, neuroinflammation, and neurodegenerative changes begin within one of three rostral brain networks involved in behavior, language, or motor function before spreading into other brain regions.

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. expert witness -- Latham & Watkins and Winston & Strawn -- no relation to anything in the paper

  7. Adam M. Staffaroni, PhD,
    8. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NIH-NIA

    Research Support, Foundations and Societies:

    1. Larry L. Hillblom Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. Bradford C. Dickerson, MD,
    9. Scientific Advisory Boards:

    1. Merck, Lilly, Biogen, Wave LifeSciences, Arkuda, Axovant

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Neuroimage: Clinical, Co-Editor in Chief; Cortex, Section Editor Hippocampus, Editorial board Neurodegenerative Disease Management, Editorial board

    Patents:

    1. NONE

    Publishing Royalties:

    1. Oxford univ press: Dementia; Cambridge Univ Press: Frontotemporal Dementia

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Piramal

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NIH P01 AG005134 (Neuroimaging Core Leader); NIH R01 AG036694 (Co- Investigator); NIH R01 AG030311 (MPI); NIH R01 AG045390 (Co- Investigator); NIH U01 AG045390 (Co-Investigator); NIH R01 AG048351 (MPI); NIH R01 AG038791 (Co-Investigator); NIH U01 AG052943 (Co-Investigator); NIH R21 AG051987 (MPI); NIH R01 DC014296 (MPI); NIH R01 AG056015 (MPI); NIH R01 AG054081 (MPI); NIH R01 MH113234 (MPI); NIH R21 AG056958 (MPI); NIH R56 AG057195 (MPI)

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. ADDF (PI)

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  9. Bradley F. Boeve, MD,
    10. Scientific Advisory Boards:

    1. Tau Consortium

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. Miller BL, Boeve BF (Eds). Behavioral Neurology of Dementia, Cambridge: Cambridge University Press, 2009, 2017.

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Grant support as an investigator in clinical trials funded by Biogen, 2018-present; Alector, 2019-present.

    Research Support, Government Entities:

    1. NIH: P50 AG016574 (2009-present), U01 AG006786 (2009- present), RO1 AG032306 (2010-present), RO1 AG041797 (2012- present), UO1 AG045390 (2014-present), U54 NS092089 (2014-present), U01 AG052943 (2016-present), R01 AG038791 (2017-present), UO1 NS100620 (2017-present), R44 AG050326 (2017-present), and R34 AG056639 (2018-present)

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Mangurian Foundation, 2011-present Little Family Foundation, 2015-present Turner Family, 2019-present

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  10. David S. Knopman, MD,
    11. Scientific Advisory Boards:

    1. Consultant Bluefield project (frontotemporal dementia) ended 2018. DIAN study DSMB (Sept 2013 - July 2019).

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Omsbudsman Neurology, currently

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) A4 clinical trial partially funded by Lilly (site PI) (2) Biogen Alzheimer Study (site PI)

    Research Support, Government Entities:

    1. NIH: R01-AG11378 ongoing, P50-AG 16574 (Mayo Alzheimer’s Disease Research Center) ongoing, U01 AG 06786 (Mayo Alzheimer Disease Patient Registry) ongoing. 1U01HL096917-01 ARIC Dementia Study. AG 037551 Chronic Kidney Disease and Cognitive functioning.

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  11. Marilu Gorno-Tempini, MD, PhD,
    12. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. --NIH/NINDS R01NS050915 (Gorno-Tempini PI), 6 years.--NIH/NIA R01 AG032306 (Rosen, PI), Senior Investigator, 6years.--NIH/NIA P01AG019724-06 (Miller, PI) 6 years--NIH/NIA 5P50AG023501-12 (Gorno-Tempini, PI), 2 years.--NIH/NIDCD K24 DC015544 (Gorno-Tempini, PI), 1 year

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. John Douglas French Alzheimer?s Foundation; Alzheimer?s Association; Larry L. Hillblom Foundation; Koret Family Foundation; McBean Family Foundation; Alzheimer?s Disease Center of California; Consortium for Frontotemporal Dementia Research.

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  12. Bruce L. Miller, MD,
    13. Scientific Advisory Boards:

    1. The Tau Consortium - Scientific Advisor The John Douglas French Foundation - Medical Advisor The Larry L. Hillblom Foundation - Medical Advisory Board The Consortium for Frontotemporal Dementia Research - Internal Advisor Global Brain Health Institute (GBHI) Co- Director University of Washington ADRC - External Advisor Stanford University ADRC - External Advisor Arizona Alzheimer’s Disease Center (ADC) - External Advisor Massachusetts Alzheimer Disease Research Center – External Advisor International Society of FTD - USA-President, Executive Committee

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Cambridge University Press Guilford Publications, Inc. Oxford University Press Neurocase Elsevier, Inc. Up-to-date Frontiers ALS/FTD Journal (Taylor & Francis) - Editorial Board

    Patents:

    1. NONE

    Publishing Royalties:

    1. (1) Behavioral Neurology of Dementia, Cambridge University Press, 2009 (2) Handbook of Neurology, Elsevier Inc., 2009 (3) The Human Frontal Lobes, Guilford Publications, 2008 (4) Frontotemporal Dementia, Oxford University Press, 2014

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Quest Diagnostics Dementia Pathway Collaboration Research Grant

    Research Support, Government Entities:

    1. (1) NIA, P50 AG23501 PI, (2004-) (2) NIA, P01 AG19724 PI, (2002-) (3) CMS, 1C1-14-001-017996 PI, (2014-) (4) NIA, T32 AG023481, Co-PI, (2010-)

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License fee payments, Technology or Inventions:

    1. Invention/Technology: Dementia Care Pathway (Suite of tools to improve dementia diagnosis in primary care settings) Source of Payment: Quest Diagnostics

    Royalty Payments, Technology or Inventions:

    1. Invention/Technology: Dementia Care Pathway (Suite of tools to improve dementia diagnosis in primary care settings) Source of Payment: Quest Diagnostics As of 11/26/2019: No royalty payments have been received yet, but do have contractual rights to receipt of future payments

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  13. William J. Jagust, MD,
    14. Scientific Advisory Boards:

    1. Banner/Genentech DSMB 2013-2019 Banner/Novartis DSMB 2014-2019

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Editorial Board Brain Imaging and Behavior. Alzheimer's Disease and Associated Disorders, Neuroimage: Clinical (current)

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Consultant Bioclinica Consultant, Lou Ruvo Center/Cleveland Clinic Consultant, Biogen Consultant Grifols Consultant CuraSen

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NIH, Principal Investigator on the following grants: AG034570 AG025303 AG044292 NIH Co-Investigator on the following grants: AG012435 AG021028 AG031563 AG019724 AG030048 AG032306 AG024904

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Tau Consortium (Rainwater Foundation) Alzheimer's Association

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  14. Adam L. Boxer, MD, PhD,
    15. Scientific Advisory Boards:

    1. Scientific advisory board/consulting for Alector, Arvinas, Arkuda, Asceneuron, Pinteon

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. I have received funding for travel from , the Movement Disorders Society, the Association for Frontotemporal Degeneration, Fidelity Biosciences Research Institute and the Tau Consortium.

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Abbvie, AGTC, Ionis, Janssen, Merck, Novartis, Sangamo, Samumed,Toyama, UCB, Lundbeck

    Speakers' Bureaus:

    1. NONE

    Other activities:

    1. Received honorarium for serving as a reviewer for the Parkinson's Study Group

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. I received research support from Avid, Biogen, BMS, C2N, Cortice, Forum, Genentech, Janssen, Pfizer, Eli Lilly, Roche and TauRx for conducting clinical trials or biomarker studies.

    Research Support, Government Entities:

    1. NIH: U54NS092089 (PI), R01AG031278 (PI), R01AG038791 (PI), R01AG032306 (co-I), R01AG022983 (Co-I)

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. The Tau Research Consortium, the Bluefield Project to Cure Frontotemporal Dementia, Corticobasal Degeneration Solutions and the Alzheimer's Association, the Association for Frontotemporal Degeneration Stock/Stock Options, Medical Equipment & Materials: Alector, Arvinas

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  15. Howard J. Rosen, MD and
    16. Scientific Advisory Boards:

    1. Scientific advisory board for Ionis pharmaceuticals Scientific advisory board for Wave pharmaceuticals

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. National Institutes of Health, multiple grants PI, Co-I State of California

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Global Brain Health Institute Association for Frontotemporal Degeneration

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  16. Gil D. Rabinovici, MD
    17. Scientific Advisory Boards:

    1. (1) Merck - scientific advisory board (2) Axon Neurosciences - scientific advisory board (3) Eisai - scientific advisory board

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Alzheimer's Association - speaking honorarium, funding for travel (2) AAN - speaking/course director honoraria (3) Merck - funding for travel (4) Tau Consortium - funding for travel

    Editorial Boards:

    1. Associate Editor for JAMA Neurology

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Avid Radiopharmaceuticals (2) GE Healthcare (3) Life Molecular Imaging (4) Eli Lilly

    Research Support, Government Entities:

    1. (1) NIH/NIA R01-AG045611, PI, 2014-2019 (2) NIH/NIA P50-AG023501, co-I, 2014-2019 (3) NIH/NIA R01-AG048234, co-I, 2015-2020 (4) NIH/NIA R01-AG038791, co-I, 2016-2021 (5) NIH/NIA R01 AG062588, co-I, 2019-2024 (6) NIH/NIA, R01 AG064314, co-I, 2019-2024 (7) NIH/NIA, R01 AG060477, co-I, 2019-2024 (8) NIH/NIA, U01 AG057195, co-PI, 2018-2023 (9) NIH/NIA, R01 AG057204, co-I, 2017-2022 (10) NIH/NIA, P01 AG019724, co-I, 2017-2022 (11) NIH/NIA, R01 AG032289, co-I, 2015-2020 (12) NIH/NINDS, R01 NS050915, co-I, 2017-2022 (13) NIH/NIA, P30 AG062422, co-I, 2019-2024

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) Alzheimer's Association, (2) John Douglas French Alzheimer's Foundation, (3)Tau Consortium, (4) American College of Radiology

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Memory and Aging Center, Department of Neurology (A.B., G.T., G.M., Y.C., L.I., J.K., A.M.S., M.G.-T., B.L.M., A.L.B., H.J.R., G.D.R.), and Department of Radiology and Biomedical Imaging (G.D.R.), University of California San Francisco; Frontotemporal Disorders Unit (B.C.D.), Department of Neurology, Massachusetts General Hospital, Boston; and Harvard Medical School, Charleston; Department of Neurology (B.F.B., D.S.K.), Mayo Clinic, Rochester, MN; Molecular Biophysics and Integrated Bioimaging Division (W.J.J., G.D.R.), Lawrence Berkeley National Laboratory, CA; and Helen Wills Neuroscience Institute (G.D.R.), University of California Berkeley.
  1. Correspondence
    Dr. Bejanin abejanin{at}santpau.cat
View Full Text

Article usage

Article usage: June 2020 to April 2022

AbstractFullPdfSource
Jun 2020192018Highwire
Jul 20207464055Highwire
Aug 20201221012Highwire
Sep 202091126Highwire
Oct 202016565Highwire
Nov 20201391310Highwire
Dec 202011952Highwire
Jan 20219146Highwire
Feb 20217576Highwire
Mar 2021911316Highwire
Apr 20217043Highwire
May 20218054Highwire
Jun 20216326Highwire
Jul 20218603Highwire
Aug 20216232Highwire
Sep 20216351Highwire
Oct 202110723Highwire
Nov 202110123Highwire
Dec 20219231Highwire
Jan 20227385Highwire
Feb 20224911Highwire
Mar 20225963Highwire
Apr 20224672Highwire

Cited By...

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me